Sector News

Epstein leaves Novartis as pharmaceuticals splits in two

May 18, 2016
Life sciences

Novartis has announced plans to divide its pharmaceuticals division into two business units, in a restructure that also sees the departure of current division head and chief executive David Epstein.

Under the new structure, Novartis Pharmaceuticals and Novartis Oncology will form the Innovative Medicines Division at the Swiss drugmaker, joining the firm’s generics/biosimilars unit Sandoz and eye unit Alcon.

The move brings some key changes at the top: Epstein has decided to leave Novartis “and explore new challenges from the US”; Paul Hudson, currently executive vice president, North America, at AstraZeneca, will lead Novartis Pharmaceuticals; and Bruno Strigini, currently head of Novartis’ oncology segment, will also lead the Novartis Oncology business unit.

The firm said it expects that the changes, which ride on the back of the successful integration of the oncology assets from GlaxoSmithkline, will help drive its growth and innovation strategy, “with an increased focus and improved execution” for both business units.

Last year the group sold off its animal health division to Eli Lilly and vaccines unit to GSK, while bringing on board GSK’s oncology assets, under a drive to streamline focus and operations.

“A split makes sense because oncology now has critical mass, following the GSK deal, and oncology is in many ways becoming a differentiated business from the rest of pharmaceuticals,” said Mick Cooper, an analyst at equity research firm Trinity Delta, reports Reuters.

By Selina McKee

Source: Pharma Times

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.